Icon Clinical Research India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 26-06-2024
- Paid Up Capital ₹ 0.10 M
as on 26-06-2024
- Company Age 20 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 24.28%
(FY 2023)
- Profit 41.92%
(FY 2023)
- Ebitda 24.85%
(FY 2023)
- Net Worth 174.20%
(FY 2023)
- Total Assets 49.68%
(FY 2023)
About Icon Clinical Research India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Denzil Benjamin, Alan Sheehan, and Bhagyaraj Jaganathan serve as directors at the Company.
- CIN/LLPIN
U74110TN2004PTC054137
- Company No.
054137
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Sep 2004
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Icon Clinical Research India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Denzil Benjamin  | Director | 26-Dec-2022 | Current |
Alan Sheehan  | Director | 18-Jul-2016 | Current |
| Bhagyaraj Jaganathan | Director | 26-Sep-2014 | Current |
Financial Performance and Corporate Structure Insights of Icon Clinical Research India.
Icon Clinical Research India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 24.28% increase. The company also saw a substantial improvement in profitability, with a 41.92% increase in profit. The company's net worth Soared by an impressive increase of 174.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Icon Clinical Research India?
In 2023, Icon Clinical Research India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pharmaceutical Research Associates India Private LimitedActive 39 years 5 monthsAlan Sheehan and Bhagyaraj Jaganathan are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Icon Clinical Research India?
Icon Clinical Research India has a workforce of 3383 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Icon Clinical Research India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Icon Clinical Research India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
